Latest news with #PharmaceuticalTechnology
Yahoo
22-07-2025
- Business
- Yahoo
Biogen to invest further $2bn in North Carolina's Research Triangle Park
Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of Biogen's late-stage clinical pipeline. Since its establishment in 1995, the company's manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally. The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP. These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation. Biogen pharmaceutical operations and technology head Nicole Murphy stated: 'We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community. 'Our manufacturing footprint in the US has played a critical role in Biogen's history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world. 'With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.' More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US. In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy. Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note. "Biogen to invest further $2bn in North Carolina's Research Triangle Park" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
18-06-2025
- Health
- Yahoo
NHS England chair suggests England can learn from European health schemes
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At the HLTH Europe conference taking place in Amsterdam, the Netherlands, from 16 to 19 June, NHS England chair Penny Dash highlighted that certain aspects of European health systems could translate well in the NHS. 'I think German payers have got absolutely amazing analytical capabilities and they can do things such as vary payment up and down, dependent on volumes of activity and demand,' said Dash. 'We could do things like that. I would also look at some bits of the French system in terms of digitalisation – there are some good examples there. I would focus on the work in all of the Nordic countries on primary care, as their models of primary care are population health-focused. The Nordic countries spend a significantly lower proportion of their health budget on hospitals than we do.' Dash spotlighted some strengths of the NHS, including genomics, access to data and evidence base. However, she acknowledged that the health system needs to better utilise patient data to advance healthcare. Dash's remarks come amid UK Health Secretary Wes Streeting's announcement to abolish NHS England, with the service set to return to government control. They also precede Streeting's upcoming unveiling of the 10-year Health Plan for the NHS, which will emphasise a move from hospital to community, from analogue to digital systems, and from sickness to prevention. Speaking on the plan, Dash added: 'What we are planning to do and are already doing are very analogous to what other countries are doing. We have looked at the rest of the world and we've asked: 'What are other people doing? What seems to be working? What seems to be having an impact?' Then draw on that. The Secretary of State has been very clear since he was in opposition, talking about the three shifts.' Earlier this month, an additional $29bn was granted to the NHS by Chancellor Rachel Reeves. The following day at the NHS ConfedExpo, Streeting acknowledged this boost as "substantial" but said reform is still essential. "NHS England chair suggests England can learn from European health schemes" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
‘Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033
The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published by GlobalData, which analysed the seven major markets of the US, UK, France, Germany, Italy, Spain, and Japan, forecasts sector sales will reach the $22.4bn figure by 2033, up from $8.5bn in 2023, reflecting a compound annual growth rate (CAGR) of 10.2%. While not as fast-growing as the weight loss market in the metabolic disease space, the AD market growth is salient given the market's size compared to other dermatology indications. GlobalData healthcare analyst, Filippos Maniatis, comments: 'AD is a growing market with an impressive pipeline of new products from current and future players in the field. The AD space was previously dominated by broad-acting immunomodulatory agents, which are now being slowly replaced by more targeted agents. This shift is likely due to better comprehension of the pathophysiology behind AD and the approval of several new systemic agents.' GlobalData is the parent company of Pharmaceutical Technology. One of those targeted agents that has taken the market by storm is Regeneron and Sanofi's jointly developed Dupixent (dupilumab), first approved in the US in 2017. The blockbuster monoclonal antibody has seen its sales increase year-over-year amid high uptake from AD – reaching $14.9bn in sales in 2024. Dupixent is approved for a range of diseases, including a lucrative asthma indication. The report says that the gap of unmet need in AD, which is closing courtesy of Sanofi and Regeneron, is set to shrink even further depending on future approvals for more targeted therapies. One modality poised as a future disruptor is the OX40 inhibitor class of drugs that work by inhibiting T-cell activation and inflammation via the OX40 receptor on the immune cells. Pipeline candidates in development include Amgen and Kyowa Kirin's rocatinlimab, Sanofi's amlitelimab, and Astria Therapeutics' telazrolimab. Another class with a potential future in AD is interleukin (IL) inhibitors. LEO Pharma, GSK, and Nektar all have assets in clinical development. Maniatis concludes: 'With multiple pipeline agents in development, key unmet needs may be further addressed. Such unmet needs include the lack of personalised treatments through improved diagnostic methods, the high cost of current therapy options, the limited therapeutic options for chronic hand eczema, and better long-term disease control and management.' "'Dupixent-fuelled' atopic dermatitis market sales to hit $22.4bn by 2033" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
02-05-2025
- Business
- Yahoo
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
While many pharmaceutical companies have calculated cost hits associated with US tariffs, they are reiterating that looming pharma-specific tariffs create an uncertain financial outlook for the year ahead. The first-quarter (Q1) earnings season has provided an opportunity for pharmaceutical companies to comment on the financial impact of existing tariffs and offer clues as to how future tariffs could affect 2025 performance. A common theme among Q1 earnings reports was a 2025 guidance that included the impact of current tariffs whilst excluding any future effects from pharmaceutical sector-specific ones. That instead left executives commenting on the nature of future impacts, as opposed to a material figure. For those who have released Q1 results, many are already performing above estimates, with executives expressing confidence in their company's ability to navigate the much-changed trade economy. Pharmaceutical Technology analysed select Q1 earnings reports and equity research notes from William Blair. Modelling has become as critical as ever for companies this year. BioMarin Pharmaceutical, for example, said that whilst its current guidance does not reflect future pharmaceutical tariffs, it is modelling all scenarios and evaluating potential mitigating tactics. Moderna stated it would incur minimal impact from potential tariffs, with the US big pharma's drug substance currently produced in the 200,000ft² manufacturing facility in Massachusetts. The company also expects new overseas production facilities to be operational this year, helping regional supplies of its products. UK-headquartered GSK, meanwhile, said it remains confident in its ability to absorb the impacts of potential pharmaceutical tariffs in the US by increasing operational efficiency, supply chain resilience and further expansion of its US manufacturing footprint. Expanding production to US manufacturing has been the name of the game for many pharma companies. Roche, for example, outlaid $50bn (SFr41.22bn) in investments for pharmaceuticals and diagnostics in the US over the next five years to counter Trump's tariffs. Johnson & Johnson (J&J), which announced its own $55m US manufacturing investment in March 2025, was one of several companies to place a number on tariff costs. It expects a $400m hit tied to existing and newly proposed tariffs, although most of this burden will fall on its medtech division. Pfizer expects a lower hit than J&J, forecasting costs of around $150m due to existing tariffs this year. Whilst other companies have been quick to double down in the US manufacturing space, CEO Albert Bourla said that uncertainty around Trump's planned pharmaceutical tariffs is deterring further investment in the country. MSD's CEO Rob Davis pointed to $200m in added costs for existing tariffs, mostly via China. The company plans to spend $9bn on US manufacturing and research and development. Regardless of how pharma companies' financials look after further tariffs are implemented, effects are still likely to be felt by patients. Analysis by GlobalData indicates that pharmaceutical tariffs could create a pivotal moment in the industry that may reshape consumer access to medicine. How companies deal with tariffs will be a key factor in dictating the prices and availability of drugs in the US in 2025. GlobalData is the parent company of Pharmaceutical Technology. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence "Q1 earnings pulse check: companies tentative on pharma-specific tariffs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
30-04-2025
- Business
- Yahoo
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the pharmaceutical supply chain. With US President Donald Trump leaning towards implementing additional tariffs on the pharmaceutical sector, there is potential to disrupt drug development costs and drug prices, with any tariffs increasing the import costs of many raw materials and active pharmaceutical ingredients, according to GlobalData, a leading data and analytics company. According to GlobalData's 2025 report, China is currently the world's second-largest single country market, following the US, with pharmaceutical market sales expected to hit 2trn yuan ($273.9bn) in 2025. On 4 April 2025, Trump imposed an additional 34% tariff on all Chinese imports, with China responding with a reciprocal 34% tariff on all goods imported from the US. The Chinese government has also subjected an additional 16 US organisations and companies to trade sanctions or export controls, as well as adding 11 companies to the unreliable entity list on 5 April 2025, limiting investment activities in China. The volatile relations between the US and China are expected to significantly affect the international pharmaceutical market, with any future-imposed pharmaceutical tariffs potentially resulting in increased costs of drugs, limited patient availability, and logistical difficulties, with several organisations considering relocation to tackle this issue. On 9 April 2025, China's Ministry of Finance announced an 84% retaliatory tariff on all goods imported from the US to take place from 10 April 2025, up from 34%, in response to Trump's recent levy hikes. This follows the US' imposition of a 125% tariff on Chinese imports on 9 April 2025, up from 104%, accelerating the trade war between the two nations. Due to the current lack of exemptions for the pharmaceutical industry by the Chinese government, imported pharmaceutical products and vaccines will be subjected to the additional tariffs. Trump has also stated that the imposed tariffs on the pharmaceutical industry will cause organisations to reshore their manufacturing to the US, with no specific timeline on when the pharmaceutical tariffs are to be imposed. "US tariffs likely to disrupt drug development costs and prices, says GlobalData" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
